Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
Natalie Staplin, Alistair Roddick, Jonathan Emberson, et al.
EClinicalMedicine (2021) Vol. 41, pp. 101163-101163
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
Paul E. Stevens, Sofia B. Ahmed, Juan Jesús Carrero, et al.
Kidney International (2024) Vol. 105, Iss. 4, pp. S117-S314
Open Access | Times Cited: 1997
Empagliflozin in Patients with Chronic Kidney Disease
William G. Herrington, Natalie Staplin, Christoph Wanner, et al.
New England Journal of Medicine (2022) Vol. 388, Iss. 2, pp. 117-127
Open Access | Times Cited: 1416
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
Nikolaus Marx, Massimo Federici, Katharina Schütt, et al.
European Heart Journal (2023) Vol. 44, Iss. 39, pp. 4043-4140
Open Access | Times Cited: 708
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Colin Baigent, Jonathan Emberson, Richard Haynes, et al.
The Lancet (2022) Vol. 400, Iss. 10365, pp. 1788-1801
Open Access | Times Cited: 611
Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
Ian H. de Boer, Kamlesh Khunti, Tami Sadusky, et al.
Diabetes Care (2022) Vol. 45, Iss. 12, pp. 3075-3090
Open Access | Times Cited: 417
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
Ian H. de Boer, Kamlesh Khunti, Tami Sadusky, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. 974-989
Open Access | Times Cited: 170
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
Brendon L. Neuen, Hiddo J.L. Heerspink, Priya Vart, et al.
Circulation (2023) Vol. 149, Iss. 6, pp. 450-462
Open Access | Times Cited: 100
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
William G. Herrington, Christoph Wanner, Jennifer B. Green, et al.
Nephrology Dialysis Transplantation (2022) Vol. 37, Iss. 7, pp. 1317-1329
Open Access | Times Cited: 95
Metformin: Therapeutic profile in the treatment of type 2 diabetes
Clifford J. Bailey
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S3, pp. 3-19
Open Access | Times Cited: 18
SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA
Patrick B. Mark, Pantelis Sarafidis, Robert Ekart, et al.
Nephrology Dialysis Transplantation (2023) Vol. 38, Iss. 11, pp. 2444-2455
Open Access | Times Cited: 40
UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE
Alistair Roddick, Alexa Wonnacott, David R. Webb, et al.
BMC Nephrology (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 35
Comparison of Effectiveness Among Different Sodium‐Glucose Cotransoporter‐2 Inhibitors According to Underlying Conditions: A Network Meta‐Analysis of Randomized Controlled Trials
Ryoma Kani, Atsuyuki Watanabe, Yoshihisa Miyamoto, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 16
Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: a Review
Reza Pishdad, Paul G. Auwaerter, Rita R. Kalyani
Current Diabetes Reports (2024) Vol. 24, Iss. 5, pp. 108-117
Closed Access | Times Cited: 15
SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health
Magdalena Madero, Glenn M. Chertow, Patrick B. Mark
Kidney Medicine (2024) Vol. 6, Iss. 8, pp. 100851-100851
Open Access | Times Cited: 10
Reducing hyperuricemic events with SGLT2 inhibitors: An updated systematic review with meta-regression
Hamlet Ghukasyan, Denilsa Navalha, Ignacio Pérez Romero, et al.
Endocrinología Diabetes y Nutrición (English ed ) (2025) Vol. 72, Iss. 1, pp. 26-36
Closed Access | Times Cited: 1
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline
Magdalena Madero, Adeera Levin, Sofia B. Ahmed, et al.
Annals of Internal Medicine (2025)
Closed Access | Times Cited: 1
The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes
Antonio Ceriello, Giuseppe Lucisano, Francesco Prattichizzo, et al.
The Lancet Regional Health - Europe (2023) Vol. 31, pp. 100666-100666
Open Access | Times Cited: 22
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an overview of 36 systematic reviews
Paschalis Karakasis, Konstantinos Pamporis, Panagiotis Stachteas, et al.
Heart Failure Reviews (2023) Vol. 28, Iss. 5, pp. 1033-1051
Closed Access | Times Cited: 17
SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
Merlin C. Thomas, Brendon L. Neuen, Stephen M. Twigg, et al.
Endocrine Connections (2023) Vol. 12, Iss. 8
Open Access | Times Cited: 15
Bioimpedance Indices of Fluid Overload and Cardiorenal Outcomes in Heart Failure and Chronic Kidney Disease: a Systematic Review
Kaitlin J. Mayne, Richard Shemilt, David Keane, et al.
Journal of Cardiac Failure (2022) Vol. 28, Iss. 11, pp. 1628-1641
Open Access | Times Cited: 21
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Baiju R. Shah, Harpreet S. Bajaj, Sonia Butalia, et al.
Canadian Journal of Diabetes (2024) Vol. 48, Iss. 7, pp. 415-424
Closed Access | Times Cited: 4
The kidney matrisome in health, aging, and disease
Franziska Lausecker, Rachel Lennon, Michael J. Randles
Kidney International (2022) Vol. 102, Iss. 5, pp. 1000-1012
Open Access | Times Cited: 18
Have SGLT-2 inhibitors DELIVERed an EMPhatic win in heart failure and chronic kidney disease?
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults with Variable Disease States: A Meta-analysis of Large Placebo-Controlled Trials
Syeda Ayesha Shah, Hasan Mushahid, Ali Salman, et al.
Drugs & Aging (2025)
Closed Access
Does plasma exchange have a role in ANCA-associated vasculitis? Viewpoint 1: plasma exchange should not be used indiscriminately
Michael Walsh
Lara D. Veeken (2025) Vol. 64, Iss. Supplement_1, pp. i64-i67
Closed Access
Page 1 - Next Page

Scroll to top